SCHEMBL186936

SCHEMBL186936

CCCC[C@H](N)C(=O)OC(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.50
PRSS1 P07477 2/20 0.45
CTSG P08311 2/20 0.45
CTRB1 P17538 2/20 0.45
CMA1 P23946 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
ALDH1A1 P00352 3/20 0.44
CYP3A4 P08684 3/20 0.44
CA2 P00918 1/20 0.44
ERAP2 Q6P179 2/20 0.42
LNPEP Q9UIQ6 2/20 0.42
SLC1A5 Q15758 1/20 0.42
TSHR P16473 4/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
PDE4D Q08499 1/20 0.42
MAPK1 P28482 2/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11403740 1.00 LMNA (0.50) LMNAPRSS1CTSGCTRB1CMA1
SCHEMBL17821459 0.94 LMNA (0.47) LMNAPRSS1CTSGCTRB1CMA1
SCHEMBL534809 0.86 DPP7 (0.48) LMNATDP1ALDH1A1SLC1A5MAPK1
SCHEMBL27792687 0.86 SLC1A5 (0.50) LMNATDP1ALDH1A1SLC1A5TSHR
SCHEMBL9724882 0.82 LMNA (0.50) LMNAPRSS1CTSGCTRB1CMA1
SCHEMBL27678034 0.82 CA2 (0.51) LMNAPRSS1CTSGCTRB1CMA1
SCHEMBL1997086 0.81 ALDH1A1 (0.45) LMNATDP1ALDH1A1SLC1A5TSHR
Hydrochloric Acid SCHEMBL6751555 0.81 SLC1A5 (0.51) LMNATDP1ALDH1A1SLC1A5TSHR
SCHEMBL7790573 0.81 LMNA (0.60) LMNAPRSS1TDP1ALDH1A1CYP3A4
SCHEMBL6668784 0.81 MARS1 (0.43) LMNATDP1ALDH1A1SLC1A5TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580746-B2 Amide linkage cyclic natriuretic peptide constructs PALATIN TECHNOLOGIES, INC. (US) 2013-11-12 US disclosed
US-8580747-B2 Cyclic natriuretic peptide constructs PALATIN TECHNOLOGIES, INC. (US) 2013-11-12 US disclosed
EP-2001518-B1 CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2013-07-10 EP disclosed
US-8114844-B2 Linear and cyclic melanocortin receptor-specific peptidomimetics PALATIN TECHNOLOGIES, INC. (US) 2012-02-14 US disclosed
EP-2004352-B1 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2012-01-04 EP disclosed
US-20110263818-A1 Peptidic Constructs with Amino Acid Surrogates PALATIN TECHNOLOGIES, INC. (US) 2011-10-27 US disclosed
US-7964181-B2 Amino acid surrogates for peptidic constructs PALATIN TECHNOLOGIES, INC. (US) 2011-06-21 US disclosed
US-7795221-B2 Linear natriuretic peptide constructs PALATIN TECHNOLOGIES, INC. (US) 2010-09-14 US disclosed
US-20100075895-A1 Cyclic Natriuretic Peptide Constructs PALATIN TECHNOLOGIES, INC. (US) 2010-03-25 US disclosed
US-20100035821-A1 Amide Linkage Cyclic Natriuretic Peptide Constructs PALATIN TECHNOLOGIES, INC. (US) 2010-02-11 US disclosed
EP-2004633-A2 LINEAR NATRIURETIC PEPTIDE CONSTRUCTS Palatin Technologies, Inc. (US) 2008-12-24 EP disclosed
EP-2004352-A2 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS Palatin Technologies, Inc. (US) 2008-12-24 EP disclosed
EP-2001518-A2 CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS Palatin Technologies, Inc. (US) 2008-12-17 EP disclosed
WO-2007115164-A9 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2007-11-29 WO disclosed
US-20070265206-A1 Cyclic Natriuretic Peptide Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-11-15 US disclosed
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-11-08 US disclosed
WO-2007115182-A2 LINEAR NATRIURETIC PEPTIDE CONSTRUCTS PALATIN TECHNOLOGIES, INC. (US) 2007-10-11 WO disclosed
WO-2007115164-A2 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES, INC. (US) 2007-10-11 WO disclosed
WO-2007115175-A2 CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS PALATIN TECHNOLOGIES, INC. (US) 2007-10-11 WO disclosed
US-20070232546-A1 Linear Natriuretic Peptide Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263818-A1 Peptidic Constructs with Amino Acid Surrogates ARGLU1, QRFPR, ARG1 LMNA 3710/4885PRSS1 778/4885CTSG 1279/4885
US-20070265206-A1 Cyclic Natriuretic Peptide Constructs NPR1, NPR3, NPPA LMNA 1311/4885PRSS1 2334/4885CTSG 2906/4885
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs ARGLU1, ARG1, QRFPR LMNA 3509/4885PRSS1 1249/4885CTSG 1334/4885
US-20100035821-A1 Amide Linkage Cyclic Natriuretic Peptide Constructs NPR1, NPR3, NPPA LMNA 719/4885PRSS1 3208/4885CTSG 2835/4885
US-20070232546-A1 Linear Natriuretic Peptide Constructs NPR1, NPR3, NPPA LMNA 644/4885PRSS1 2365/4885CTSG 3116/4885
US-20100075895-A1 Cyclic Natriuretic Peptide Constructs NPR1, NPR3, NPPA LMNA 1311/4885PRSS1 2334/4885CTSG 2906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.